Sariel007 OP t1_ixv5kr0 wrote
Reply to comment by demonmariner in A novel medication for hemophilia B has just been approved by the Food and Drug Administration. The treatment is a form of gene therapy, intended to replace a dysfunctional gene that leaves people unable to control their bleeding. by Sariel007
One dose cure instead of "...patients will undergo regular infusions of their missing clotting factor. Though effective at stopping spontaneous bleeding, these infusions are not a cure and in the most severe cases, people may need to get them every two to three days—a costly and time-consuming measure. "
AinsiSera t1_ixvnosp wrote
I read elsewhere that those treatments easily add up to $100k/month, so honestly $3.5 mil is pretty cost effective competitively.
RO489 t1_ixvt06y wrote
Depending if your insurance/ employer agree. Since insurance is mostly tied to employment in the US, they aren't firing the math of a lifetime cost. I'd imagine single payer would be a no brainer, but if you are an employer, it'll increase everyone's cost.
Another argument in favor of single payer.
scarlet_sage t1_ixvnm9y wrote
It did not appear to be a cure, though it doesn't explain why.
>It also appeared to lower the rate of bleeding problems by 54% in one trial, and it reduced the need for regular infusions of clotting factors....
>it should reduce the frequency of expensive transfusions; they also say that the drug’s effectiveness is expected to last for several years at least.
Viewing a single comment thread. View all comments